Taysha Gene Therapies to Participate in Upcoming June Investor Healthcare Conferences

Jefferies Virtual Healthcare Conference on June 2, 2021 at 10:30 am ET

Goldman Sachs 42^nd Annual Global Healthcare Conference on June 10, 2021 at 5:30 pm ET

JMP Securities Life Science Conference on June 16, 2021 at 12:30 pm ET

DALLAS--(BUSINESS WIRE)--Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivitol-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS) in both rare and large patient populations, today announced its participation in a virtual fireside chat for the Jefferies Virtual Healthcare Conference, Goldman Sachs 42^nd Annual Global Healthcare Conference, and the JMP Securities Life Science Conference.

Conferences Details:

Event:	Jefferies Virtual Healthcare Conference
Date:	Wednesday, June 2, 2021
Time:	10:30 am ET
Format:	Fireside chat
Participants:	RA Session II, President, Founder and CEO
	Dr. Suyash Prasad, Chief Medical Officer and Head of R&D
	Kamran Alam, Chief Financial Officer
Event:	Goldman Sachs 42^nd Annual Global Healthcare Conference
Date:	Thursday, June 10, 2021
Time:	5:30 pm ET
Format:	Fireside chat
Participants:	RA Session II, President, Founder and CEO
	Dr. Suyash Prasad, Chief Medical Officer and Head of R&D
	Kamran Alam, Chief Financial Officer
Event:	JMP Securities Life Science Conference
Date:	Wednesday, June 16, 2021
Time:	12:30 pm ET
Format:	Fireside chat
Participants:	RA Session II, President, Founder and CEO
	Dr. Suyash Prasad, Chief Medical Officer and Head of R&D
	Kamran Alam, Chief Financial Officer

Webcasts for these conferences will be available in the “Events & Media” section of the Taysha corporate website at https://ir.tayshagtx.com/news-events/events-presentations. Archived versions of the webcasts will be available on the website for 60 days.

About Taysha Gene Therapies

Taysha Gene Therapies (Nasdaq: TSHA) is on a mission to eradicate monogenic CNS disease. With a singular focus on developing curative medicines, we aim to rapidly translate our treatments from bench to bedside. We have combined our team’s proven experience in gene therapy drug development and commercialization with the world-class UT Southwestern Gene Therapy Program to build an extensive, AAV gene therapy pipeline focused on both rare and large-market indications. Together, we leverage our fully integrated platform—an engine for potential new cures—with a goal of dramatically improving patients’ lives. More information is available at www.tayshagtx.com.